PolarityTE Commences Phase III Trial for SkinTE in Diabetic Foot Ulcers

PolarityTE Commences Phase III Trial for SkinTE in Diabetic Foot Ulcers Overview Company: PolarityTE Indication: Diabetic foot ulcers Drug: SkinTE Trial Phase: Phase 3 NCT ID: Not provided PolarityTE has initiated the first subject screening for their Phase III pivotal study, entitled 'COVER DFUS II', which investigates the use of their novel product SkinTE for the treatment of Wagner grade 1 di..